After the bell today a Form 144 filing (get it here in the April 30 link) was released concerning everybody’s favorite pink sheet bioturd, Coronacrapper extraordinaire, Cytodyn (CYDY).
Yes, CEO Nader “The Nadir” Pourhassan sold 4.8mm shares on 30 April, while telling the world the amazing wonders of Cytodyn‘s ancient one time AIDS-then cancer-now-coronavirus drug. Said the company that day:
Of course the NEJM letter about those renal transplant patients shows the results of leronlimab were nothing short of, well, nothing.
The shares did see very strong stock promotion though. Strong enough for The Nadir to dump all that stock, that appears to be at zero basis. Nice work.
THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.